It’s been two and a half years since regulations in the Deficit Reduction Act on bundled drug sales has gone into effect, and the industry is still struggling to determine standard practices. Pharmaceutical and biotech manufacturers lack clear guidance and with tight government scrutiny of discount allocations for bundled sales, they run the costly risk of non-compliance. One firm has already been charged with improper bundling practices and others are sure to follow. Fortunately, help is on the way.
Read more: Establishing Best Practices for Government Pricing and Bundled Sales

iMANY now offers further support for meeting Government Pricing (GP) mandates thanks to its strategic alliance with Polaris Contracting Solutions, a leading management consulting firm in healthcare compliance. Life science and pharmaceutical companies can now gain industry best practices with the ease and efficiencies of a Business Process Outsourcing (BPO) model. Polaris, which already delivers BPO services to over 30 pharmaceutical companies, will offer a hosted solution that leverages iMANY’s best-in-class software solutions combined with Polaris’ advisory services and process expertise to ensure optimal contract performance and government compliance.
Read more: Optimizing Healthcare Compliance through Best-of-Breed Outsourced Software & Service

The complexity of validating and processing rebate claims challenges many pharmaceutical manufacturers. While outsourcing the task can be costly and using internal staff can significantly reduce efficiency, the risk of revenue leakage and noncompliance is too high to ignore. Manufacturers who follow best practices are turning to in-house, automated solutions, such as iMANY Validata, to retain control over their data and significantly increase validation accuracy. Implementing a flexible system that easily integrates with legacy systems and virtually any contract management system delivers rapid and tangible ROI along the following business areas: